Literature DB >> 188578

Neutrophilic granulocytes in acute bacterial infection. Sequential studies on lysozyme, myeloperoxidase and lactoferrin.

N E Hansen, H Karle, V Andersen, J Malmquist, G E Hoff.   

Abstract

The changes in intraneutrophilic and plasma concentrations of the three antibacterial proteins lysozyme, lactoferrin, and myeloperoxidase were studied sequentially during acute bacterial infection in nine patients. Intraneutrophilic concentrations of the three proteins were decreased by more than 50% during the 1st week of infection, followed by a slow increase over the following 2 weeks. Nadir values coincided with maximal toxic granulation of the neutrophils. The data suggest that neutrophilic granulocytes are deficient during early bacterial infection, possibly because of deficient synthesis of antibacterial proteins in the bone marrow, and that neutrophil toxic granulation is the visual counterpart of this defect. The plasma concentrations of the three proteins showed considerable differences: whereas plasma lysozyme did not show any sequential changes, plasma myeloperoxidase was high at the start of infection and quickly decreased towards normal values, and plasma lactoferrin, high in the first samples, showed a secondary peak 1 week after onset of disease, before normalization was seen. These differences may result from differences in the signals are specific for the individual antibacterial protein and not for the different types of neutrophil granules.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 188578      PMCID: PMC1540984     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  22 in total

1.  Neutrophil kinetics in corticosteroid induced neutrophilia measured by plasma lysozyme.

Authors:  H Karle; N E Hansen
Journal:  Scand J Haematol       Date:  1975-05

2.  [Rapid etiological diagnosis in bacterial meningitis].

Authors:  G E Hoff; N Høiby
Journal:  Ugeskr Laeger       Date:  1975-07-21

3.  Dohle bodies and other granulocytic alterations during chemotherapy with cyclophosphamide.

Authors:  T ITOGA; J LASZLO
Journal:  Blood       Date:  1962-12       Impact factor: 22.113

4.  Character of azurophil and specific granules purified from human polymorphonuclear leukocytes.

Authors:  J K Spitznagel; F G Dalldorf; M S Leffell; J D Folds; I R Welsh; M H Cooney; L E Martin
Journal:  Lab Invest       Date:  1974-06       Impact factor: 5.662

5.  Neutrophil granulocyte function in bacterial infections.

Authors:  C O Solberg; K B Hellum
Journal:  Lancet       Date:  1972-10-07       Impact factor: 79.321

6.  The effect of leukocyte hydrolases on bacteria. II. The synergistic action of lysozyme and extracts of PMN, macrophages, lymphocytes, and platelets in bacteriolysis.

Authors:  N Neeman; M Lahav; I Ginsburg
Journal:  Proc Soc Exp Biol Med       Date:  1974-09

7.  Plasma myeloperoxidase and lactoferrin measured by radioimmunoassay: relations to neutrophil kinetics.

Authors:  N E Hansen; J Malmquist; J Thorell
Journal:  Acta Med Scand       Date:  1975-12

8.  Inhibition by sulfonamides of the candidacidal activity of human neutrophils.

Authors:  R I Lehrer
Journal:  J Clin Invest       Date:  1971-12       Impact factor: 14.808

9.  The influence of phagocytosis on the intracellular distribution of granule-associated components of polymorphonuclear leucocytes.

Authors:  Z A COHN; J G HIRSCH
Journal:  J Exp Med       Date:  1960-12-01       Impact factor: 14.307

10.  The development of neutrophilic polymorphonuclear leukocytes in human bone marrow.

Authors:  D F Bainton; J L Ullyot; M G Farquhar
Journal:  J Exp Med       Date:  1971-10-01       Impact factor: 14.307

View more
  12 in total

1.  Myeloperoxidase-oxidase oxidation of cysteamine.

Authors:  B E Svensson; S Lindvall
Journal:  Biochem J       Date:  1988-01-15       Impact factor: 3.857

2.  Proteomic analysis of a matrix stone: a case report.

Authors:  Benjamin K Canales; Lorraine Anderson; LeeAnn Higgins; Chris Frethem; Alice Ressler; Il Won Kim; Manoj Monga
Journal:  Urol Res       Date:  2009-12

3.  Persistent bactericidal defect in neutrophils from a young woman who recovered from toxic shock syndrome.

Authors:  E M Berger; C J Beehler; J E Repine
Journal:  Inflammation       Date:  1986-12       Impact factor: 4.092

4.  Modeling an autism risk factor in mice leads to permanent immune dysregulation.

Authors:  Elaine Y Hsiao; Sara W McBride; Janet Chow; Sarkis K Mazmanian; Paul H Patterson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-16       Impact factor: 11.205

5.  Human neutrophil lipocalin is a unique marker of neutrophil inflammation in ulcerative colitis and proctitis.

Authors:  M Carlson; Y Raab; L Sevéus; S Xu; R Hällgren; P Venge
Journal:  Gut       Date:  2002-04       Impact factor: 23.059

Review 6.  Iron and infection.

Authors:  E D Weinberg
Journal:  Microbiol Rev       Date:  1978-03

7.  Effects of surgery on neutrophil granulocyte function.

Authors:  H El-Maallem; J Fletcher
Journal:  Infect Immun       Date:  1981-04       Impact factor: 3.441

8.  Peroxidasin-mediated bromine enrichment of basement membranes.

Authors:  Cuiwen He; Wenxin Song; Thomas A Weston; Caitlyn Tran; Ira Kurtz; Jonathan E Zuckerman; Paul Guagliardo; Jeffrey H Miner; Sergey V Ivanov; Jeremy Bougoure; Billy G Hudson; Selene Colon; Paul A Voziyan; Gautam Bhave; Loren G Fong; Stephen G Young; Haibo Jiang
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-22       Impact factor: 11.205

9.  Lactoferrin release and interleukin-1, interleukin-6, and tumor necrosis factor production by human polymorphonuclear cells stimulated by various lipopolysaccharides: relationship to growth inhibition of Candida albicans.

Authors:  C Palma; A Cassone; D Serbousek; C A Pearson; J Y Djeu
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

10.  Lactoferrin in relation to acute phase proteins in sera from newborn infants with severe infections.

Authors:  T J Gutteberg; B Haneberg; T Jørgensen
Journal:  Eur J Pediatr       Date:  1984-04       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.